Big Pharma R&D Chiefs to Converge at Biocom’s 2026 Conference
Event summary
- Biocom’s 2026 Global Partnering & Investor Conference (Feb. 24–26) will feature a keynote panel with R&D heads from AbbVie, Amgen, and Eli Lilly.
- Panelists include Jay Bradner (Amgen), Jonathon Sedgwick (AbbVie), and Daniel Skovronsky (Eli Lilly).
- The session will discuss AI in drug discovery, biotech-pharma collaboration, and innovation trends.
- Over 500 investors and executives from 20+ countries are expected to attend.
The big picture
This gathering of top pharmaceutical R&D leaders underscores the industry’s focus on AI-driven innovation and cross-sector collaboration. With multibillion-dollar portfolios at stake, the insights shared could reshape biotech-pharma partnerships in 2026.
What we're watching
- Innovation Trends
- How AI adoption will accelerate drug discovery timelines across Big Pharma.
- Biotech Collaboration
- Whether smaller biotechs can effectively partner with large pharma on R&D initiatives.
- Investor Sentiment
- The pace at which conference discussions translate into tangible investment opportunities.
Related topics